MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
about
Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer ChemotherapyCombinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysisBST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer.Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaPD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
P2860
MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MEK Inhibition Overcomes Cispl ...... on in Squamous Cell Carcinoma.
@en
type
label
MEK Inhibition Overcomes Cispl ...... on in Squamous Cell Carcinoma.
@en
prefLabel
MEK Inhibition Overcomes Cispl ...... on in Squamous Cell Carcinoma.
@en
P2093
P50
P1476
MEK Inhibition Overcomes Cispl ...... ion in Squamous Cell Carcinoma
@en
P2093
Chonglei Bi
Hsien Chun Ng
Jean-Paul Thiery
Jingshan Ho
Kian Ngiap Chua
Min En Nga
Ross Andrew Soo
Wee Joo Chng
Weijie Richard Ong
Wen Jing Sim
P304
P356
10.1158/1535-7163.MCT-15-0062
P577
2015-05-04T00:00:00Z